[1]袁 萍,刘 敏,刘建兵,等.龙胆泻肝丸联合鼓室内注射倍他米松治疗分泌性中耳炎疗效研究[J].陕西中医,2024,(9):1218-1221.[doi:DOI:10.3969/j.issn.1000-7369.2024.09.015]
　YUAN Ping,LIU Min,LIU Jianbing,et al.Efficacy of Longdan Xiegan pill combined with intratympanic injection of betamethasone in the treatment of secretory otitis media[J].,2024,(9):1218-1221.[doi:DOI:10.3969/j.issn.1000-7369.2024.09.015]
点击复制

龙胆泻肝丸联合鼓室内注射倍他米松治疗分泌性中耳炎疗效研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年9期
页码:
1218-1221
栏目:
临床研究
出版日期:
2024-09-05

文章信息/Info

Title:
Efficacy of Longdan Xiegan pill combined with intratympanic injection of betamethasone in the treatment of secretory otitis media
作者:
袁 萍1; 刘 敏1; 刘建兵1; 康厚墉2
(1.绵阳市第三人民医院耳鼻咽喉科, 四川 绵阳 621000; 2.重庆医科大学附属第一医院耳鼻咽喉头颈外科,重庆 400700)
Author(s):
YUAN Ping; LIU Min; LIU Jianbing; KANG Houyong
(The Third Hospital of Mianyang Otolaryngology Department,Mianyang 621000,China)
关键词:
分泌性中耳炎;  龙胆泻肝丸;  鼓室内注射治疗;  倍他米松;  T淋巴细胞亚群;  中耳积液;  炎症因子
Keywords:
Secretory otitis media;  Longdan Xiegan pill;  Intratympanic injection therapy;  Betamethasone;  T-lymphocyte subsets;  Middle ear effusion;  Inflammatory factors
分类号:
R 764.21
DOI:
DOI:10.3969/j.issn.1000-7369.2024.09.015
文献标志码:
A
摘要:
目的:探讨龙胆泻肝丸联合鼓室内注射倍他米松治疗分泌性中耳炎(OME)临床疗效及其对患者外周血T淋巴细胞亚群和中耳积液中高迁移率族蛋白1(HMGB1)、肿瘤坏死因子(TNF)-α、白细胞介素(IL)-33水平的影响。方法:选取252例OME患者,随机分为两组各126例。对照组给予鼓室内注射倍他米松治疗,在此基础上,观察组联合龙胆泻肝丸治疗。比较两组临床疗效、外周血T淋巴细胞亚群和中耳积液中HMGB1、TNF-α、IL-33等水平。结果:观察组总有效率91.37%高于对照组的82.54%(P<0.05)。治疗后,两组病情严重程度评分、气导平均听阈、骨导平均听阈、外周血CD8+和中耳积液中HMGB1、TNF-α、IL-33水平都显著降低,而外周血CD3+、CD4+水平和CD4+/CD8+都显著增加,都以观察组为甚(P<0.05)。观察组不良反应率10.3%与对照组8.7%比较无统计学差异(P>0.05)。结论:龙胆泻肝丸联合鼓室内注射倍他米松治疗OME的总体疗效确切,可改善患者听力,改善外周血T淋巴细胞亚群失衡以及抑制中耳积液中HMGB1、TNF-α、IL-33表达,且安全性好。
Abstract:
Objective:To investigate the clinical efficacy of Longdan Xiegan pill combined with intratympanic injection of betamethasone in the treatment of secretory otitis media(OME)and its effect on the levels of high mobility group protein 1(HMGB1),tumor necrosis factor-α(TNF)-α and interleukin(IL)-33 in peripheral blood T lymphocyte subsets and middle ear effusion.Methods:A total of 252 OME patients were randomly divided into two groups with 126 patients in each group.The control group was treated with betamethasone injection in tympanic chamber.On this basis,the observation group was treated with Longdan Xiegan pill.The clinical efficacy,levels of HMGB1,TNF-α and IL-33 in peripheral blood T lymphocyte subsets and middle ear effusion were compared between the two groups.Results:The total effective rate of 91.37% in the observation group was higher than that of 82.54% in the control group(P<0.05).After treatment,disease severity score,mean audibility threshold of air conduction,mean audibility threshold of bone conduction,HMGB1,TNF-α and IL-33 levels of peripheral blood CD8+ and middle ear effusion were significantly decreased in both groups,while peripheral blood CD3+,CD4+ and CD4+/CD8+ levels were significantly increased,especially in the observation group(P<0.05).The adverse reaction rate was 10.3% in the observation group and 8.7% in the control group(P>0.05).Conclusion:The overall efficacy of Longdan Xiegan pill combined with betamethasone injection in tympanic cavity in the treatment of OME is accurate,and it can improve the hearing of patients,improve the imbalance of peripheral blood T lymphocyte subgroups,and inhibit the expression of HMGB1,TNF-α and IL-33 in middle ear effusions,with good safety.

参考文献/References:

[1] 刘鲜妮,张瑞永,蔺晓玲.半夏厚朴汤治疗分泌性中耳炎的临床观察[J].陕西中医,2016,37(5):598-599.
[2] 赵兴泉,钟渠,陈茜.分泌性中耳炎研究现状[J].国际耳鼻咽喉头颈外科杂志,2017,41(3):136-140.
[3] IKEDA R,HIDAKA H,ITO M,et al.Pharmacotherapy focusing on for the management of otitis media with effusion in children:Systematic review and meta-analysis[J].Auris Nasus Larynx,2022,49(5):748-754.
[4] 包晓青,陈钰欣,俞玲佳,等.糖皮质激素不同给药方式治疗138例分泌性中耳炎患儿的疗效[J].中国妇幼保健,2022,37(13):2410-2413.
[5] 陈建伟,刘蕾,李晓光,等.耳内镜下鼓室内注射地塞米松治疗突发性耳聋效果分析[J].健康必读,2023(5):1-2.
[6] 国家药典委员会.中华人民共和国药典(2020年版 一部)[M].北京:中国医药科技出版社,2020:809-810.
[7] 刘娅,杨军,张杰,等.临床实践指南:分泌性中耳炎(更新版)[J].听力学及言语疾病杂志,2016,24(5):499-519.
[8] 江坚,周雪.从痰饮论治慢性分泌性中耳炎[J].陕西中医,2020,41(10):1458-1460.
[9] CHOFFOR-NCHINDA E,SIAFA A B.Otitis media with effusion in Africa-prevalence and associated factors:A systematic review and meta-analysis[J].Laryngoscope Investig Otolaryngol,2020,5(6):1205-1216.
[10] 王影.糖皮质激素对分泌性中耳炎的治疗效果及复发率[J].中国药物经济学,2021,16(10):69-71.
[11] 李熙星,陈雨濛,张光远,等.类固醇激素治疗儿童分泌性中耳炎的临床研究进展[J].中华耳科学杂志,2020,18(3):459-463.
[12] 吴强.复方倍他米松经鼓室内给药治疗突发性耳聋的效果研究[J].健康前沿,2019,28(4):204.
[13] 周春巧.龙胆泻肝汤的药理作用及其临床应用研究进展[J].临床合理用药杂志,2018,11(11C):180-181.
[14] 陈敏,夏寿明.黄芩对小鼠抗炎镇痛作用的研究[J].安徽农学通报,2020,26(15):34-35,118.
[15] 程玉鹏,姜丽丽,王语哲,等.柴胡皂苷a药理学研究进展[J].中华中医药学刊,2021,39(4):24-27.
[16] 尉瑞,袁艳红,陈璐璐,等.龙胆泻肝汤对分泌性中耳炎血清炎性因子、相关蛋白及免疫功能的影响[J].中国实验方剂学杂志,2019,25(8):14-19.
[17] 崔喜财,赵恒威,张鲁壮,等.急性分泌性中耳炎患者外周血T淋巴细胞亚群与中耳积液炎症因子的相关性[J].川北医学院学报,2021,36(1):68-71.
[18] 金阳,葛金环,刘思琦,等.当归多糖的化学结构、药理作用及构效关系研究进展[J].中医药信息,2022,39(2):69-77.
[19] 王小兰,段鹏飞,杨梦,等.生地黄多糖对环磷酰胺诱导的免疫抑制小鼠的免疫调节作用研究[J].上海中医药大学学报,2021,35(1):55-60,92.
[20] 邢金燕,刘鑫国,谭建成,等.微小RNA-411-3p在分泌性中耳炎表达及其对炎症的调控机制[J].中华实验外科杂志,2022,39(12):2417-2420.
[21] 苏雅静,罗安平,叶琳,等.分泌性中耳炎患者耳积液HMGB1、IL-6表达及意义[J].中国听力语言康复科学杂志,2022,20(2):98-101.
[22] 许倩云,崔昊晶.分泌性中耳炎患者血清中HMGB1、TLR2的表达及临床意义分析[J].局解手术学杂志,2021,30(12):1085-1088.
[23] 李欣,杨东,张笑颜.LTD4、IL-6以及TNF-α在分泌性中耳炎中耳积液中的表达及意义[J].基因组学与应用生物学,2019,38(11):5181-5186.
[24] LIAO Z,TU B,SUN L,et al.Interleukin-33 and thymic stromal lymphopoietin are primary cytokines involved in the Th1/Th2 inflammatory response in chronic secretory otitis media[J].Eur J Inflamm,2022,17(2):202-211.
[25] 卜妍红,陆婷,吴虹,等.栀子化学成分及药理作用研究进展[J].安徽中医学院学报,2020,39(6):89-93.

备注/Memo

备注/Memo:
基金项目:重庆市卫生和计划生育委员会中医药科技项目(ZY201802143)
更新日期/Last Update: 2024-09-09